{
    "clinical_study": {
        "@rank": "46796", 
        "arm_group": {
            "arm_group_label": "Asenapine", 
            "description": "Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England."
        }, 
        "brief_summary": {
            "textblock": "This post-marketing Modified Prescription-Event Monitoring (M-PEM) safety study of asenapine\n      (SYCREST\u00ae) is to be carried out by the Drug Safety Research Unit (DSRU) as part of the Risk\n      Management Plan required by the Committee for Medicinal Products for Human Use (CHMP) to\n      further investigate the safety profile of asenapine in clinical practice. The aim of this\n      study is to proactively capture safety and drug utilisation data in the post-marketing phase\n      of license approval of asenapine as prescribed to patients by general practitioners (GPs) in\n      England. This data is obtained through the completion of questionnaires by GPs."
        }, 
        "brief_title": "An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bipolar I Disorder", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients prescribed asenapine for any indication by NHS GPs in England.\n\n          -  Patients for whom a study questionnaire containing useful information has been\n             returned, will be included in the study cohort regardless of the dose or frequency of\n             administration of asenapine, and irrespective of whether any medicines are\n             concurrently administered.\n\n        Exclusion Criteria:\n\n          -  patient no longer registered with the practice\n\n          -  patient for whom no information is provided on study questionnaire\n\n          -  patients for whom information provided on study questionnaire relates to another\n             antipsychotic drug\n\n          -  patients for whom the index date is an improbable date (i.e. before market launch\n             date)\n\n          -  patients for whom the GP reports that the patient did not take or was never\n             prescribed asenapine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients prescribed asenapine for any indication by NHS GPs in England."
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765127", 
            "org_study_id": "Asenapine ModPEM"
        }, 
        "intervention_browse": {
            "mesh_term": "Asenapine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Southampton", 
                    "country": "United Kingdom", 
                    "state": "Hampshire", 
                    "zip": "SO31 1AA"
                }, 
                "name": "Drug Safety Research Unit (for data collation and analysis only)"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Post-Authorization Modified Prescription-Event Monitoring Safety Study to Monitor the Safety and Utilization of Asenapine (Sycrest) in the Primary Care Setting in England", 
        "overall_official": {
            "affiliation": "Drug Safety Research Unit", 
            "last_name": "Saad Shakir, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence rates of these risks will be quantified:\nSomnolence and sedation\nWeight gain\nOral hypoaesthesia\nSwelling of the tongue and throat\nAllergic reactions (Type 1 hypersensitivity)", 
            "measure": "Incidence rate of selected important identified and potential risks", 
            "safety_issue": "Yes", 
            "time_frame": "At least 3 months after drug is first prescribed."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765127"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Drug Safety Research Unit, Southampton, UK", 
            "investigator_full_name": "Professor Saad Shakir", 
            "investigator_title": "Director", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Drug Safety Research Unit, Southampton, UK", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Professor Saad Shakir", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}